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Context: Reducedhealth-relatedquality of life (HRQoL) is common inpatientswithhypoparathyroidism
treated conventionally with calcium and active vitamin D supplements.
Objective: To examine the effects of recombinant human parathyroid hormone [rhPTH(1-84)] on
HRQoL as measured by the 36-Item Short-Form Health Survey (SF-36) during a multinational,
randomized, placebo-controlled study.
Patients: Adults (N = 122) with chronic hypoparathyroidism.
Intervention(s): After an optimization period when calcium and/or active vitamin D supplements
were adjusted to reach target serum calcium levels (8.0 to 9.0 mg/dL; 2.0 to 2.2 mmol/L), patients
were randomly assigned to receive placebo (n = 39) or rhPTH(1-84) (n = 83) (starting dose, 50 mg/d,
could be titrated up to 100 mg/d); supplement doses were adjusted to maintain target serum
calcium levels.
Main OutcomeMeasure(s): Change from baseline (postoptimization, at randomization) to week 24
in HRQoL as assessed by the SF-36.
Results: Overall, the between-group differences were not statistically significant. However, in the
rhPTH(1-84) group, there were significant improvements in the physical component summary score
(P = 0.004), and in body pain (P, 0.05), general health (P, 0.05), and vitality (P, 0.001) domains as
compared with baseline values. In the placebo group, there were no significant changes for any
domains. The magnitude of change between 0 and 24 weeks in SF-36 scores was negatively
correlated with baseline scores, such that patients with lower HRQoL at baseline were more
likely to experience improvement in response to treatment.
Conclusion: Treatment with rhPTH(1-84) may improve HRQoL in adults with hypoparathyroidism.
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Hypoparathyroidism is a rare endocrine disorder char-acterized by hypocalcemia and hyperphosphatemia
due to low or absent circulating levels of parathyroid
hormone (PTH). Conventional treatment of hypopara-
thyroidism consists of oral calcium supplements and
active forms of vitamin D. Conventional treatment is
often associated with incomplete control of symptoms
and poor well-being (1, 2), suggesting that there is re-
duced health-related quality of life (HRQoL) in this
patient population (3). Several recent studies have re-
ported various aspects of well-being that were impaired
in patients with hypoparathyroidism compared with
healthy individuals or patients with other metabolic
disorders. A study of German patients reported that
25 women with postsurgical hypoparathyroidism had
higher global complaint scores, with predominant in-
creases in subscores for anxiety, compared with women
who had prior thyroid surgery but retained normal
parathyroid function (4). Similarly, another study found
that Danish women with both postsurgical hypothy-
roidism and hypoparathyroidism had lower scores in
most domains of the 36-Item Short-Form Health Survey
(SF-36) than women with only postsurgical hypothy-
roidism or than age-matched control subjects (5). In a
Norwegian study of patients with hypoparathyroidism,
SF-36 scores were significantly lower than the normative
data, with lower scores observed in surgical cases com-
pared with nonsurgical cases (6). A study of 688 patients
from a Danish national registry who had postsurgical
hypoparathyroidism showed these patients had a higher
incidence of depression and other psychiatric symptoms
compared with 2064 matched control subjects (7). Fi-
nally, a US, Internet-based survey of 374 patients with
hypoparathyroidism showed that most had fatigue, as
well as emotional and cognitive impairments (8). It is also
noteworthy that these symptoms are often unexpected or
underappreciated. For example, in a US study, 340 pa-
tients with postsurgical hypoparathyroidism had symp-
toms that were considerably worse than anticipated by
102 experienced endocrine surgeons and 200 healthy
subjects given the routine preoperative description of
hypoparathyroidism as a complication of neck surgery
(9). Finally, all prior studies of PTH replacement therapy
in hypoparathyroidism have shown that HRQoL at
baseline (i.e., while receiving conventional therapy) was
lower than in the general population (10–13).
In this study, we analyzed data from a randomized,
double-blind, placebo-controlled, phase 3 study, REPLACE
(14, 15), the clinical trial that led to the approval of
recombinant human PTH [rhPTH(1-84)] for the treat-
ment of chronic hypoparathyroidism in adults (16, 17) to
determine whether rhPTH(1-84) could improve HRQoL
over what can be achieved with optimized conventional
treatment with calcium and active vitamin D alone. This
information would add to previous studies that have not
been conclusive or lacked a placebo-treated control group
(10–13). Additionally, as a multinational study, REPLACE
presented an opportunity to conduct a post hoc analysis
with regard to geographic heterogeneity among the three
regions that participated in the study: North America,
Western Europe, and Central/Eastern Europe, which
only included Hungary.
Materials and Methods
Patients and study design
Detailed inclusion and exclusion criteria have been reported
byMannstadt et al. (15) and Clarke et al. (14). Briefly, the study
enrolled patients between 18 and 85 years old with chronic
hypoparathyroidism based on hypocalcemia and documented
serum PTH levels below the lower limit of the normal range.
Patients with known or suspected mutations in the calcium-
sensing receptor gene were excluded. The study was conducted
in accordance with Good Clinical Practice guidelines and the
Declaration of Helsinki, the protocol was approved by the
institutional review boards, and all study participants provided
written informed consent.
After enrollment, patients underwent an optimization period
lasting 2 to 16 weeks, during which active vitamin D (calcitriol
or alfacalcidol) and calcium doses were adjusted to achieve
albumin-corrected serum calcium levels between 7.5 mg/dL
(1.9 mmol/L) and the upper limit of normal, but ideally
within a target range of 8.0 to 9.0 mg/dL (2.0 to 2.2 mmol/L).
Serum levels of 25-hydroxyvitamin D were optimized to be
between 30 ng/mL (75 nmol/L) and 100 ng/mL (250 nmol/L),
and magnesium deficiency [defined as values ,1.3 mEq/L
(0.7 mmol/L)] was corrected.
After daily doses of calcium and active vitamin Dwere stable
for 2 weeks, patients were randomly assigned in a double-
blinded manner to receive once-daily subcutaneous injections
of either placebo or 50 mg rhPTH(1-84) in a 1:2 ratio. The
24-week treatment period began with a titration phase, during
which the rhPTH(1-84) dosewas increased and active vitaminD
and calcium doses were reduced while maintaining albumin-
corrected serum calcium at or above baseline levels [target level:
between 7.5mg/dL (1.9mmol/L) and the upper limit of normal].
The first increase of rhPTH(1-84) to 75 mg/d could occur at
week 2, and the second increase to 100mg/d could occur at week
4. The titration phase was followed by a maintenance phase for
the remainder of the treatment period. The dose of rhPTH(1-84)
could be decreased at any time, if necessary, but not increased
during this latter period. At any time during the treatment
period, adjustments were permitted in the doses of active vi-
tamin D and calcium supplements to maintain serum calcium in
the target range and to reduce hypercalciuria. After 24 weeks,
rhPTH(1-84) was discontinued, baseline oral calcium and active
vitamin D were resumed, and patients were monitored for
another 4 weeks.
HRQoL assessments and statistical analysis
The impact of rhPTH(1-84) on HRQoL was assessed in
REPLACE using the SF-36, version 2, as an exploratory end
point. The questionnaires were administered at randomization
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(postoptimization baseline) and after 4, 12, and 24 weeks of
study drug treatment. The SF-36 survey consists of 36 questions
grouped into eight domains of physical and mental health:
physical functioning (PF), role-physical (RP), bodily pain (BP),
general health (GH), vitality (VT), social functioning (SF), role-
emotional, and mental health (MH). These eight domains are
then summarized into a physical component summary (PCS)
score and an MH component summary (MCS) score. There is a
limited range of responses for the survey questions, which are
scored using the Likert method of summated ratings. Because
the questions differed in the maximum possible score on the
scale, each score was recalculated on a 0 to 100 scale expressed
as a norm-based score [i.e., relative to 2009 normal population
mean (standard deviation) values of 50 (10)] (18), with lower
scores corresponding to greater disability. The minimally im-
portant difference (MID) for group mean for the individual
domains of SF-36 version 2 and summary scores are between 2
and 3 points (18). TheseMID values were derived from anchors
that are relevant for all patients regardless of the specific
condition (18).
This analysis used data based on the intent-to-treat pop-
ulation that had at least one postbaseline HRQoL measure-
ment (14). Within- and between-treatment–group analyses of
HRQoL overall and by geographic region were prespecified.
However, the methods used to analyze this exploratory end
point were updated from the initial statistical analysis plan to
use a mixed-effect model for repeated measures (MMRM)
analysis. The MMRM analysis has the advantage of assessing
data from all visits simultaneously, using a restricted maximum
likelihood–based approach (19). The model included the fixed
categorical effects of rhPTH(1-84) treatment, region, sex, visit,
and treatment-by-visit interaction, as well as the continuous,
fixed covariates of age, baseline HRQoL, and baseline-by-visit
interaction. Within-patient errors were modeled using an un-
structured covariance matrix. All analyses were performed
using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Of the 122 patients with at least one postbaseline HRQoL
measurement, 83 were in the rhPTH(1-84) group and 39
were in the placebo group, reflecting the 2:1 randomiza-
tion. Table 1 summarizes key patient demographic and
clinical characteristics at baseline (i.e., postoptimization
randomization). Similar to the demographics for hypo-
parathyroidism in the United States and elsewhere (2),
most patients were women (rhPTH[1-84], 77%; placebo,
82%) who developed hypoparathyroidism after thyroid
surgery (rhPTH[1-84], 71%; placebo, 72%). There was a
wide range of daily doses of calcium (1.0 to 12.0 g/d) and
active vitamin D (calcitriol or equivalent dose of 0.3 to
4.0 mg/d), but there was no statistically significant dif-
ference between treatment groups at baseline. Likewise,
there were no statistically significant differences at baseline
between treatment groups regarding age, sex, body mass
index, duration of hypoparathyroidism, etiology, albumin-
corrected serum calcium level, PTH levels, and SF-36
PCS and MCS. At baseline, several SF-36 domain
scores were below those of the norm-based population,
although the differences were small [rhPTH(1-84) and
Table 1. Patients’ Baseline Characteristics
Variable Placebo (n = 39) rhPTH(1-84) (n = 83) P Valuea
Age, mean (SD), y 49.5 (13.3) 46.6 (12.3)
Female 32 (82.1) 64 (77.1) 0.639
Body mass index, mean (SD), kg/m2 28.9 (5.4) 29.1 (6.1)
Duration of hypoparathyroidism, y
Mean (SD) 11.8 (8.1) 14.6 (11.2)
#5 9 (23.1) 15 (18.1)
.5–10 13 (33.3) 27 (32.5)
.10 17 (43.6) 41 (49.4)
Postsurgical etiology 28 (71.8) 59 (71.1) 1.000
Prescribed calcium dose at baseline, mg/d
Mean (SD) 1932 (892.0) 2185 (1477.3)
022000 29 (74.4) 56 (67.5)
.2000 10 (25.6) 27 (32.5)
Prescribed vitamin D dose at baseline, mg/db
Mean (SD) 1.1 (0.7) 1.1 (0.9)
Low dose 3 (7.7) 6 (7.2)
Medium dose 12 (30.8) 21 (25.3)
High dose 24 (61.5) 56 (67.5)
Albumin-corrected serum calcium at baseline, mean (SD), mg/dL 8.6 (0.6) 8.5 (0.8)
Parathyroid hormone at baseline, mean (SD), ng/Lc 6.5 (6.5) 6.3 (8.7)
Data given as no. (%) unless otherwise indicated.
aCalculated based on t tests, except for the variables of female sex and etiology, which were based on the Fisher exact test.
bFor calcitriol, low dose is #0.25 mg/d; medium dose, .0.2520.5 mg/d; and high dose, .0.5 mg/d. For alfacalcidol, low dose is ,0.50 mg/d; medium
dose, .0.521.0 mg/d; and high dose, is .1.0 mg/d.
cNormal range in adults is 14272 ng/L.
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placebo, respectively, mean (standard error): GH, 46.1
(1.3) and 46.3 (2.0); RP, 47.8 (1.0) and 46.3 (1.6); BP,
48.3 (1.2) and 48.1 (1.4); SF, 48.8 (1.2) and 48.1 (1.6);
PF, 49.2 (1.0) and 45.4 (1.5)].
The multinational REPLACE study enrolled patients
at sites in Western Europe (Belgium, Denmark, France,
the United Kingdom, and Italy), Central/Eastern Europe
(only Hungary), and North America (Canada and the
United States). Baseline SF-36 scores within each region
are listed in Table 2 for each treatment arm; there was a
range of scores across the regions for any one SF-36
domain, but there were no statistically significant dif-
ferences between treatment groups in any given region
except Hungary. The baseline SF-36 scores tended to
be higher in the patients randomly assigned to the
rhPTH(1-84) arm than in those in the placebo arm, with
between-group differences significant for the PF (P =
0.031) and VT (P = 0.025) domains and approaching
significance for RP (P = 0.073).
Table 3 presents the mean baseline and 24-week
values for the eight SF-36 domains and two composite
scores (PCS and MCS). For each treatment group, we
included the unadjusted means and standard errors; to
analyze the effect of treatment, we used the MMRM-
adjusted least squares (LS) mean change from baseline
with corresponding P values comparing within and
between treatment groups. Within the rhPTH(1-84)
group, four SF-36 domains were statistically signifi-
cant when analyzing LS mean change from baseline
from the multivariate adjusted model [BP, 2.0 (P ,
0.05); GH, 2.0 (P , 0.05);VT, 3.7 (P , 0.001); and
PCS, 2.0 (P , 0.05)]. In contrast, there were no sig-
nificant changes from baseline in any SF-36 domain
within the placebo group. The between-group differ-
ences in LS mean change from baseline to 24 weeks
were not statistically significant.
Independent predictors or modifiers of change
in HRQoL
Serum calcium
We found no significant correlation between baseline
HRQoL and either serum calcium level at baseline or
change in serum calcium level between enrollment and
randomization (effect of optimization). Additionally,
changes in HRQoL during the treatment phase were not
correlated with changes in serum calcium level.
Baseline HRQoL
For all SF-36 domains, baseline HRQoL score was a
significant (negative) predictor of change inHRQoL after
treatment (data not shown): patients who started with
lower scores (i.e., greater disability) had a greater increase
from baseline. Figure 1 illustrates negative correlation
between the baseline score and the magnitude of changes
in PCS and MCS scores in response to treatment.
Sex
In this analysis, sex was included a priori in theMMRM
analysis and appeared to confound the relationship between
rhPTH(1-84) and HRQoL. We did not find a consistent
effect of sex on change in HRQoL. When compared with
men, women had an average 2.5 lower score for PF (P =
0.016), a 2.4 higher RP (P = 0.040), and a 3.1 higher score
for role-emotional (P = 0.017). Additionally, the treatment
effect of rhPTH(1-84), as measured by LS mean changes in
HRQoL in the rhPTH(1-84) group, were substantially di-
minished for several domains (.10%) when sex was in-
cluded in themodel (RP by 35%, BP by 13%,MHby 31%,
and the MCS score by 49%). Consequently, the magni-
tude and significance of improvement in HRQoL and the
number of domains with significant improvement in the
rhPTH(1-84)-treated group were diminished as a result
of including sex in the model.
Table 2. Regional Baseline SF-36 Scores
SF-36
Domain
Hungary (n = 23) North America (n = 62) Western Europe (n = 37)
Placebo,
n = 7
rhPTH(1-84)
(n = 16) P Value
Placebo
(n = 20)
rhPTH(1-84)
(n = 42) P Value
Placebo
(n = 12)
rhPTH(1-84)
(n = 25) P Value
PF 42.1 (1.7) 49.4 (1.9) 0.031 51.6 (1.5) 51.3 (1.3) 0.888 40.0 (3.3) 45.5 (2.1) 0.151
RP 40.8 (2.4) 48.5 (2.5) 0.073 52.2 (1.6) 50.6 (1.1) 0.411 42.6 (3.3) 43.3 (2.1) 0.843
BP 48.1 (4.1) 49.7 (3.0) 0.754 50.8 (1.7) 49.9 (1.5) 0.708 47.0 (3.0) 46.0 (2.2) 0.775
GH 41.1 (3.6) 45.3 (2.7) 0.379 53.9 (1.8) 50.4 (1.5) 0.192 41.0 (3.3) 40.6 (2.4) 0.926
VT 45.0 (4.0) 55.9 (2.5) 0.025 52.0 (1.8) 50.6 (1.6) 0.589 42.4 (4.0) 43.4 (2.5) 0.829
SF 46.6 (4.0) 51.1 (2.1) 0.292 51.1 (1.9) 51.0 (1.4) 0.991 44.0 (3.2) 43.5 (2.3) 0.908
RE 43.2 (4.1) 47.7 (3.0) 0.409 50.4 (2.0) 52.9 (1.0) 0.215 45.7 (3.4) 44.6 (2.0) 0.766
MH 46.4 (5.1) 53.3 (2.3) 0.164 52.3 (1.6) 53.1 (1.4) 0.742 46.1 (3.5) 44.8 (2.2) 0.754
PCS 42.5 (1.5) 47.8 (2.2) 0.146 52.1 (1.5) 49.6 (1.4) 0.266 41.5 (3.2) 44.2 (2.1) 0.479
MCS 46.5 (5.1) 52.7 (2.4) 0.216 51.3 (2.1) 52.8 (1.4) 0.533 46.5 (3.5) 44.2 (2.2) 0.575
Data given as mean (SE) unless otherwise indicated. For all domains, normal population has the mean of 50 and a standard deviation of 10.
Abbreviation: RE, role-emotional.
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Thyroid function
At baseline, thyroid function test results were either
normal or showed a suppressed but stable thyroid-
stimulating hormone level (a common finding in pa-
tients with prior history of thyroid cancer). Furthermore,
there were no changes in thyroid status between ran-
domization and the end of study in either group (data
not shown).
Geographic region
A preliminary MMRM analysis with an interaction
term for treatment by region showed significance for
several SF-36 domains indicating effect modification by
region. Therefore, a sensitivity analysis was conducted to
further examine the effect of rhPTH(1-84) on HRQoL
when stratified by region.
The results show that the LS mean changes from
baseline to week 24 in the SF-36 domains in patients from
the sites within North America andWestern Europe were
similar to each other, whereas the SF-36 changes in the
Hungarian patients were different. As shown in Table 4,
rhPTH(1-84) treatment in the North American and
Western European sites was associated with significant
increases in change from baseline in seven of the 10
domains (PF, P, 0.001; RP, P, 0.05; BP,P, 0.05; GH,
P , 0.05; VT, P , 0.001; MH, P , 0.05; PCS, P ,
0.001), with no significant changes in the placebo group.
In addition, comparison of the placebo and rhPTH(1-84)
LS mean change from baseline values indicated signifi-
cant differences between treatment groups for the RP
(P, 0.05), VT (P , 0.05), and PCS (P = 0.01) domains.
Conversely, at the Hungarian sites, there was no increase
in scores from baseline in the rhPTH(1-84) treatment
group but rather a trend toward decreased scores (not
statistically significant).
Temporal patterns in HRQoL
The statistically significant changes seen in HRQoL
for the sites in North America and Western Europe were
further investigated to more precisely delineate temporal
changes throughout the time points at which the data
were collected (i.e., weeks 4, 12, and 24; Fig. 2). In pa-
tients who received rhPTH(1-84), increases in PF, GH,
VT, and PCS were already observed at the earliest time
point (week 4) and were maintained throughout the
study. The increase in the BP domain observed at week 24
was also significant at week 4 but fluctuated midstudy.
The RP and MH domains gradually increased and
reached significance at week 24. In the placebo arm,
HRQoL did not change for any domain (Fig. 2).
Discussion
We examined HRQoL as measured by the SF-36 survey
during the REPLACE clinical study, the pivotal trial that
showed efficacy of rhPTH(1-84) for the treatment of
adults with chronic hypoparathyroidism. The differences
between the treatment groups were not statistically sig-
nificant. In patients who received placebo, HRQoL did
not change between randomization and 24 weeks of
treatment despite achievement of target serum levels of
calcium. In contrast, there were improvements in several
Table 3. SF-36 Scores at Baseline and After 24 Weeks of Treatment
SF-36
Domain
Placebo (n=39) rhPTH(1-84) (n=83)
rhPTH(1-84)
vs Placebo
Baseline Week 24
LS Mean
Change (SE)a P Valueb Baseline Week 24
LS Mean
Change (SE)a P Valueb P Valuec
PF 45.4 (1.5) 46.8 (1.7) 1.3 (1.2) 0.278 49.2 (1.0) 50.1 (1.1) 1.4 (0.8) 0.071 0.894
RP 46.3 (1.6) 47.0 (1.6) 20.9 (1.3) 0.476 47.8 (1.0) 49.7 (1.0) 1.2 (0.9) 0.167 0.143
BP 48.1 (1.4) 47.9 (1.7) 20.6 (1.4) 0.662 48.3 (1.2) 50.8 (1.3) 2.0 (1.0) 0.042 0.106
GH 46.3 (2.0) 46.6 (2.1) 20.2 (1.1) 0.843 46.1 (1.3) 48.5 (1.2) 2.0 (0.8) 0.016 0.088
VT 47.7 (1.8) 50.0 (1.9) 1.6 (1.4) 0.258 49.5 (1.3) 53.0 (1.1) 3.7 (1.0) ,0.001 0.173
SF 48.1 (1.6) 48.5 (1.7) 20.6 (1.4) 0.677 48.8 (1.2) 50.0 (1.1) 0.4 (1.0) 0.695 0.541
RE 47.1 (1.8) 49.0 (1.6) 20.2 (1.3) 0.885 49.5 (1.1) 49.9 (1.0) 20.6 (0.9) 0.528 0.795
MH 48.8 (1.9) 50.0 (2.0) 20.3 (1.2) 0.807 50.8 (1.2) 52.8 (1.1) 1.2 (0.9) 0.175 0.283
PCS 46.0 (1.3) 46.3 (1.6) 20.1 (1.0) 0.961 47.3 (1.1) 49.3 (1.0) 2.0 (0.7) 0.004 0.074
MCS 48.9 (1.9) 50.5 (1.9) 0.2 (1.2) 0.892 50.4 (1.2) 51.9 (1.1) 0.7 (0.8) 0.427 0.704
Data given as unadjusted mean (SE) unless otherwise indicated. The analysis used an MMRM. The analyses included the fixed, categorical effects of
rhPTH(1-84), treatment, region, sex, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of age, baseline HRQoL score, and
the baseline-by-visit interaction. An unstructured covariance structure shared across treatment groups was used to model the within-patient errors. For all
domains, normal population has the mean of 50 and a standard deviation of 10.
Abbreviation: RE, role-emotional.
aLS mean change is the model-based mean change from baseline to week 24.
bWithin-treatment–group P value.
cBetween-treatment–group P value.
726 Vokes et al Effect of rhPTH(1-84) Therapy on HRQoL J Clin Endocrinol Metab, February 2018, 103(2):722–731
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/103/2/722/4584210 by Sem
m
elw
eis U
niversity user on 07 July 2019
SF-36 domains as well as the PCS score in patients treated
with rhPTH(1-84). GH, VT, BP, and the PCS scores all
had statistically significant increases from baseline in
patients who received rhPTH(1-84). Given that the MID
for the group mean for the individual domains of SF-36
version 2 and summary scores are between 2 and 3, we
note that, on average, patients treated with rhPTH(1-84)
in our study achieved the MID thresholds for the VT
domain and for PCS when using the model-based mean
change, and additionally for the BP domain when us-
ing the unadjusted mean change (Table 3). An impor-
tant qualification to this and all studies of HRQoL in
hypoparathyroidism is that the SF-36 is not a disease-
specific instrument. As a generic health-status assess-
ment questionnaire, it cannot assess the impact and
symptoms specifically related to hypoparathyroidism.
Although investigators await the development of a
validated, disease-specific, patient-reported outcomes
tool for hypoparathyroidism, the SF-36 is a standard,
validated tool for measuringHRQoL in general. Although
it has been shown that hypothyroidism is, itself, associated
with reduced HRQoL (5), it is not likely that our results
could be explained by abnormal thyroid status. Our pa-
tients had stable thyroid function test results at random-
ization and no change during the study.
Our results are consistent with findings from two
previous open-label studies, one from New York (10, 11)
and the other from Italy (12). However, the magnitude of
increase in the HRQoL scores in the prior studies was
greater than that observed in REPLACE (10–12), pos-
sibly because patients in REPLACE had higher baseline
scores. It is important to note, however, that at least some
HRQoL scores, although higher than in the aforemen-
tioned investigator-initiated studies, were nevertheless
lower than those in the normal population, even after the
optimization period that was part of the REPLACE
Figure 1. Change from baseline in SF-36 PCS and MCS scores. The change in (A) PCS score and (B) MCS score from baseline to week 24 is
plotted as a function of baseline score in patients who received rhPTH(1-84) or placebo (red squares and blue circles, respectively). The regression
line for rhPTH(1-84)-treated patients (solid red line) had a slope that did not encompass zero, whereas the slope of the line for placebo-treated
patients (broken blue line) did. For all domains, normal population has the mean of 50 and a standard deviation of 10. CI, confidence interval.
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design. It is unlikely that the differences in effect size
among the three studies were due to the use of different
versions of the SF-36 (version 1 in earlier open label
studies; version 2 in REPLACE), because the two versions
produce similar scores when used in the normal pop-
ulation (20). Another possible explanation is study de-
sign. Patients in REPLACEwent through an optimization
period of 2 to 16 weeks before randomization, during
which supplement doses were adjusted and vitamin D
deficiency and hypomagnesemia corrected. Albumin-
corrected serum calcium levels increased by 0.46 mg/dL
(0.12 mmol/L) during the optimization period. This
improved biochemical control, in itself, may have im-
proved the patients’ well-being, leading to the higher
baseline scores, but we cannot prove this, because we did
not have HRQoL data at screening. During optimization,
patients had greater frequency of medical encounters and
biochemical testing than is typical in clinical practice, and
many had increases in serum calcium to levels that are
higher than is usually recommended for this population.
Despite that additional effort and biochemical im-
provement, some HRQoL scores still remained below
normal after optimization of conventional therapy.
In contrast to the consistency of our results with the
open-label studies mentioned, our findings from RE-
PLACE are unlike those from, to our knowledge, the only
other double-blind, placebo-controlled trial to use
rhPTH(1-84) in patients with hypoparathyroidism. In
the investigator-initiated study from Denmark (13), 62
patients were randomly assigned 1:1 to placebo or a
fixed dose of rhPTH(1-84) 100 mg/d. Of note, doses of
supplemental calcium or active vitamin D were not
reduced unless a patient developed hypercalcemia,
which occurred with higher frequency in patients re-
ceiving rhPTH(1-84). In response to treatment, scores
improved in more domains in the placebo group than in
the rhPTH(1-84) group, possibly because of higher
prevalence of hypercalcemia in the latter. In contrast,
Table 4. Regional SF-36 Scores at Baseline and After 24 Weeks of Treatment
SF-36
Domain
North America/Western Europe
Placebo (n = 32) rhPTH(1-84) (n = 67)
rhPTH(1-84)
vs Placebo
Baseline Week 24
LS Mean
Change (SE)a P Valueb Baseline Week 24
LS Mean
Change (SE)a P Valueb P Valuec
PF 46.4 (1.9) 46.8 (2.0) 0.9 (1.2) 0.461 49.2 (1.2) 51.4 (1.1) 3.0 (0.8) ,0.001 0.120
RP 47.8 (1.9) 47.5 (1.8) 21.3 (1.3) 0.349 47.6 (1.2) 50.5 (1.1) 2.1 (0.9) 0.018 0.030
BP 48.1 (1.5) 47.7 (1.9) 20.7 (1.5) 0.633 47.9 (1.3) 51.0 (1.3) 2.6 (1.0) 0.013 0.064
GH 47.7 (2.3) 48.6 (2.3) 0.5 (1.2) 0.675 46.3 (1.5) 49.0 (1.4) 2.1 (0.9) 0.016 0.282
VT 48.5 (2.1) 49.2 (2.2) 0.6 (1.4) 0.667 47.7 (1.5) 52.8 (1.2) 4.8 (1.0) ,0.001 0.013
SF 48.5 (1.8) 48.7 (1.9) 20.4 (1.6) 0.784 48.2 (1.4) 50.2 (1.3) 1.2 (1.1) 0.255 0.364
RE 48.1 (2.0) 49.9 (1.7) 0.2 (1.3) 0.903 50.0 (1.2) 51.1 (1.0) 0.6 (0.9) 0.460 0.743
MH 49.5 (2.0) 50.6 (2.0) 20.0 (1.3) 0.988 50.1 (1.4) 53.1 (1.2) 2.2 (0.9) 0.017 0.147
PCS 46.9 (1.6) 46.6 (2.0) 20.5 (1.1) 0.640 47.2 (1.3) 50.0 (1.1) 2.7 (0.7) ,0.001 0.010
MCS 49.5 (2.1) 51.0 (1.9) 0.5 (1.3) 0.723 49.8 (1.4) 52.2 (1.2) 1.7 (0.9) 0.057 0.404
Hungary
Placebo (n = 7) rhPTH(1-84) (n = 16)
PF 42.1 (1.7) 46.9 (2.3) 4.5 (3.3) 0.183 49.4 (1.9) 45.3 (2.6) 22.8 (2.3) 0.244 0.065
RP 40.8 (2.4) 45.3 (4.1) 2.6 (3.1) 0.411 48.5 (2.5) 46.7 (2.4) 22.6 (2.4) 0.290 0.157
BP 48.1 (4.1) 48.3 (4.0) 0.1 (4.3) 0.973 49.7 (3.0) 50.1 (3.4) 0.6 (3.3) 0.848 0.914
GH 41.1 (3.6) 39.1 (4.2) 22.7 (2.7) 0.323 45.3 (2.7) 46.6 (2.6) 1.2 (2.0) 0.570 0.187
VT 45.0 (4.0) 53.0 (3.5) 6.4 (3.5) 0.088 55.9 (2.5) 53.8 (2.7) 20.6 (2.6) 0.813 0.103
SF 46.6 (4.0) 48.0 (4.0) 1.1 (3.3) 0.752 51.1 (2.1) 48.9 (2.7) 21.7 (2.4) 0.472 0.464
RE 43.2 (4.1) 45.7 (4.7) 20.2 (3.6) 0.956 47.7 (3.0) 45.5 (2.9) 24.0 (2.7) 0.151 0.345
MH 46.4 (5.1) 47.9 (5.9) 1.5 (2.2) 0.504 53.3 (2.3) 51.5 (2.6) 22.2 (1.7) 0.223 0.148
PCS 42.5 (1.5) 45.2 (2.3) 2.6 (2.7) 0.345 47.8 (2.2) 46.7 (2.5) 20.1 (2.1) 0.976 0.378
MCS 46.5 (5.1) 48.9 (5.5) 0.1 (3.1) 0.964 52.7 (2.4) 50.9 (2.7) 24.1 (2.2) 0.085 0.254
Data given as unadjustedmean (SE) unless otherwise indicated. The analysis used anMMRM. The analyses included the fixed, categorical effects of rhPTH
(1-84) treatment, sex, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of age, baseline HRQoL score, and the baseline-
by-visit interaction. An unstructured covariance structure shared across treatment groups was used to model the within-patient errors. For all domains,
normal population has the mean of 50 and a standard deviation of 10.
Abbreviation: RE, role-emotional.
aLS mean change is the model-based mean change from baseline to week 24.
bWithin-treatment–group P value.
cBetween-treatment–group P value.
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our study shows improvements in several HRQoL do-
mains in patients receiving rhPTH(1-84) and no im-
provements in patients receiving placebo, despite similar
levels of serum calcium in the two groups at baseline and
at 24 weeks. A possible limitation to our study is that the
reductions in supplement doses may have led at least
some of our patients to believe that they were randomly
assigned to receive the active drug, which might have
affected their responses to the SF-36 questionnaires. It is
not likely, however, that the difference between our
study and the Danish study could be attributed to pa-
tients in REPLACE guessing that they were receiving the
active drug. Danish patients receiving the active drug
also had dose reductions or elimination of supplement
because they developed hypercalcemia with greater
frequency than the placebo-treated patients (21).
Identifying patients who have the greatest potential
to experience improvements in HRQoL with treatment
is important because it could guide clinicians in selecting
patients who should be considered for PTH therapy, in
addition to the consideration of objective biochemical
parameters. We sought potential predictors of HRQoL
response by examining their associations with the
changes in the SF-36 scores using the REPLACE trial
data. In a separate analysis, we found that routinely
measured fasting serum calcium levels at baseline or at
24 weeks, or the differences between the two, were not
associated with the HRQoL responses. This observation
Figure 2. Change in SF-36 scores and albumin-corrected total serum calcium levels. A time-course plot of the change from baseline to weeks 4,
12, and 24 in patients from North American and Western European sites who received rhPTH(1-84) or placebo (black and gray symbols,
respectively). *P , 0.001 for rhPTH(1-84) vs baseline; †P , 0.05 for rhPTH(1-84) vs baseline; ‡P , 0.001 for placebo vs baseline; §P , 0.05 for
placebo vs baseline. RE, role-emotional; SE, standard error.
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does not necessarily indicate that control of serum cal-
cium has no bearing on HRQoL. One way in which
clinical data could fail to detect a relationship between
serum calcium level and HRQoL is that single calcium
measurements may not reflect serum calcium levels
throughout the entire day, which may have a greater
influence on overall well-being. The mechanism by which
rhPTH(1-84) treatment improves HRQoL could not be
elucidated in this study but may be related to more stable
(or less variable) 24-hour profile of serum calcium level
(which could not be assessed in the study), or an as yet
unidentified effect of rhPTH(1-84).
Interestingly, we found that baseline HRQoL scores
negatively correlated with response such that patients
with low baseline scores (i.e., greater disability) had
greater improvements in scores. This suggests that pa-
tients with poor HRQoL while receiving conventional
therapy might receive this added benefit from rhPTH(1-
84) treatment. Although sex was a significant confounder
in the analysis, there were not consistent sex-based dif-
ferences in the response, suggesting that women and men
may experience a HRQoL benefit from PTH therapy.
Because REPLACE was an international study, it
afforded the opportunity to examinewhether the effects are
influenced by geographic region. We observed differences
in baselineHRQoL scores, with the highest values reported
by patients fromNorth America and lower values reported
by patients in sites in Western Europe and Hungary. In
addition, at Hungarian sites (Table 2), baseline HRQoL
scores were not balanced between treatment arms, with a
tendency toward higher scores in patients randomly
assigned to receive rhPTH(1-84). Because we have ob-
served that higher baseline scores were a negative predictor
of response to rhPTH(1-84) in the entire study population,
this imbalance may have contributed to the finding that
patients from Hungarian sites did not show improvement
with rhPTH(1-84) treatment. In addition, the investigator
from Hungary (P. Lakatos, personal communication) has
suggested that there may have been a misinterpretation of
the questionnaires by their patients despite their use of a
validated translation into Hungarian. Our data do not
allow us to determine the basis of these differing findings at
Hungarian sites. Of note, in the other two regions (North
America and Western Europe), which had balanced
baseline scores between the groups, there was a significant
increase in several scores in rhPTH(1-84)-treated but not in
placebo-treated patients, with the differences between the
groups reaching statistical significance for at least some
domains (Table 4).
We also examined the time course of HRQoL changes
during REPLACE. For the domains that showed the
greatest improvements in the rhPTH(1-84)-treated pa-
tients, the significant changes were already noted at
4 weeks and persisted through the study (Fig. 2), which is
consistent with data observed in the open-label study
from New York (10). It is not likely that these im-
provements were simply due to the changes in serum
calcium level, because we found no significant correlation
between serum calcium level and changes in the SF-36
scores. Furthermore, the time course of SF-36 changes
does not parallel the changes in serum calcium level seen
in Fig. 2. It should also be noted that at 24weeks, patients
in the rhPTH(1-84) group had higher SF-36 scores
compared with placebo-treated patients, despite the se-
rum calcium level being practically identical in the two
groups (Fig. 2).
In conclusion, we found that although there was no
overall between-group difference, HRQoL improved in
several domains in the rhPTH(1-84)-treated group but
not in the placebo-treated group. Furthermore, in pa-
tients from North America and Western Europe, the
HRQoL improvements in response to rhPTH(1-84) were
greater and were statistically significantly different from
placebo. The greatest improvements were noted in those
who started with the lowest HRQoL levels. Thus, poor
HRQoL in patients receiving conventional therapy may
represent a clinical situation in which a trial of rhPTH(1-
84) therapy could be considered.
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